

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. In the Phase III STARGLO trial, the combination of glofitamab and gemcitabine/oxaliplatin resulted in which of the following outcomes compared to rituximab with gemcitabine/oxaliplatin for patients with transplant-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?
  - a. Inferior overall survival (OS)
  - b. Noninferior OS
  - c. Significantly improved OS
2. A subgroup analysis of progression-free survival (PFS) and OS from the Phase III POLARIX trial suggests that the regimen of pola-R-CHP may be more efficacious for which patients with newly diagnosed DLBCL?
  - a. Patients with germinal center B cell-like cell-of-origin subtype
  - b. Patients with activated B-cell-like cell-of-origin subtype
  - c. Patients with bulky disease present
  - d. Patients younger than age 65
3. Which of the following statements best describes outcomes from the Phase III inMIND trial comparing the triplet combination of tafasitamab with lenalidomide/rituximab (R<sup>2</sup>) to R<sup>2</sup> alone for patients with R/R follicular lymphoma?
  - a. PFS was similar in both study arms
  - b. PFS was significantly improved with R<sup>2</sup> alone
  - c. PFS was significantly improved with tafasitamab and R<sup>2</sup>
4. AZD0486 is a bispecific antibody targeting...
  - a. CD3/CD20
  - b. CD3/CD19
  - c. CD3/GPRC5D
  - d. CD4/CD8
5. Which of the following descriptions best reflects results with lisocabtagene maraleucel in the marginal zone lymphoma cohort of the Phase II TRANSCEND FL trial?
  - a. No improvement in overall response rate (ORR)
  - b. Nonsignificant trend toward improved ORR
  - c. Statistically significant improvement in ORR